25 October 2018

Osimertinib for Lung Cancer

cover

There is currently an unmet need for targeted lung cancer therapy with improved central nervous system penetration and activity against central nervous system metastases. This study on “CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)” is the first global phase III study to show osimertinib having robust and durable efficacy against central nervous system metastases and disease progression (J Clin Oncol. 2018 Jul 30:JCO2018779363. doi: 10.1200/JCO.2018.77.9363. [Epub ahead of print]).

Anyone interested in future collaboration in this field of research is welcome to contact our key investigator Prof Tony Mok, Chairman of Our Department of Clinical Oncology. Prof Mok’s research focuses on biomarker and molecular targeted therapy in lung cancer. He is the co-founder of the Lung Cancer Research Group, and has led multiple multinational studies leading to the establishment of the global standard on personalized medicine for lung cancer.

Read the full arcticle: http://ascopubs.org/doi/abs/10.1200/JCO.2018.77.9363?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

More on our research: https://research.med.cuhk.edu.hk

back